Akira Katoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Akira Katoh has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Suita, Japan
1 shared publication - Haruna Matsuda-Hirose
Department of Dermatology, Faculty of Medicine, Oita University, Oita, Japan
1 shared publication - Hiroyuki Kouji
Translational Chemical Biology Laboratory, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu, Oita, 879-5593, Japan
1 shared publication - Jun Adachi
Laboratory of Proteomics for Drug Discovery, Center for Drug Design Research National Institutes of Biomedical Innovation, Health and Nutrition Ibaraki Osaka Japan
1 shared publication - Kenji Mizuguchi
National Institutes of Biomedical Innovation, Health and Nutrition
1 shared publication Mari Nogami‐Itoh
Laboratory of Bioinformatics, Artificial Intelligence Center for Health and Biomedical Research National Institutes of Biomedical Innovation Health and Nutrition Settsu Osaka Japan
1 shared publication
Latest Publications
- 4 November 2026
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 20 (6)
Discovering Biomarkers for Idiopathic Pulmonary Fibrosis by Correlating Serum Extracellular Vesicle Proteins With Clinical Data
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease with a poor prognosis due to the irreversible loss of lung structure. Unfortunately, distinguishing between this condition and other interstitial pneumonias (IPs) is quite difficult. Hence, we herein present a machine learning method to identify IPF biomarkers by correlating serum extracellular vesicle proteomic data with clinical data for 507 patients with IPs and 39 healthy control subjects. We applied multi‐class sparse correlation analysis to detecting proteins associated with each disease‐specific IP phenotype, and identified surfactant protein B (SFTPB) and BPI fold containing family B member 1 (BPIFB1) as potential IPF biomarker candidates for discriminating IPF from other IPs, with area under the receiver operating characteristic curve scores of 0.679 and 0.678, respectively, outperforming existing biomarkers for IPF. Combinations of SFTPB and BPIFB1 achieved better discriminative performance over the use of SFTPB or BPIFB1 individually. The identified biomarker candidates can be expected to facilitate the noninvasive diagnosis of IPF.
- 4 November 2026
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 20 (6)
Discovering Biomarkers for Idiopathic Pulmonary Fibrosis by Correlating Serum Extracellular Vesicle Proteins With Clinical Data
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease with a poor prognosis due to the irreversible loss of lung structure. Unfortunately, distinguishing between this condition and other interstitial pneumonias (IPs) is quite difficult. Hence, we herein present a machine learning method to identify IPF biomarkers by correlating serum extracellular vesicle proteomic data with clinical data for 507 patients with IPs and 39 healthy control subjects. We applied multi‐class sparse correlation analysis to detecting proteins associated with each disease‐specific IP phenotype, and identified surfactant protein B (SFTPB) and BPI fold containing family B member 1 (BPIFB1) as potential IPF biomarker candidates for discriminating IPF from other IPs, with area under the receiver operating characteristic curve scores of 0.679 and 0.678, respectively, outperforming existing biomarkers for IPF. Combinations of SFTPB and BPIFB1 achieved better discriminative performance over the use of SFTPB or BPIFB1 individually. The identified biomarker candidates can be expected to facilitate the noninvasive diagnosis of IPF.
- Open Access
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (6) , 631-639
Selective Inhibition of β-Catenin/Co-Activator Cyclic AMP Response Element-Binding Protein-Dependent Signaling Prevents the Emergence of Hapten-Induced Atopic Dermatitis-Like Dermatitis
The canonical Wnt/β-catenin signaling pathway is a fundamental regulatory system involved in various biological events. ICG-001 selectively blocks the interaction of β-catenin with its transcriptional co-activator cyclic AMP response element-binding protein (CBP). Recent studies have provided convincing evidence of the inhibitory effects of ICG-001 on Wnt-driven disease models, such as organ fibrosis, cancer, acute lymphoblastic leukemia, and asthma. However, the effects of ICG-001 in atopic dermatitis (AD) have not been investigated. To investigate whether β-catenin/CBP-dependent signaling was contributed in the pathogenesis of AD and ICG-001 could be a therapeutic agent for AD. We examined the effects of ICG-001 in an AD-like murine model generated by repeated topical application of the hapten, oxazolone (Ox). ICG-001 or vehicle alone was injected intraperitoneally every day during the development of AD-like dermatitis arising from once-daily Ox treatment. Ox-induced AD-like dermatitis characterized by increases in transepidermal water loss, epidermal thickness, dermal thickness accompanied by increased myofibroblast and mast cell counts, and serum levels of thymic stromal lymphopoietin and thymus and activation-regulated chemokine, and decreases in stratum corneum hydration, were virtually normalized by the treatment with ICG-001. Elevated serum levels of periostin tended to be downregulated, without statistical significance. These results suggest that β-catenin/CBP-dependent signaling might be involved in the pathogenesis of AD and could be a therapeutic target.
- 1 January 2019
- Published by XMLink in Annals of Dermatology
- Vol. 31 (6) , 631-639
Open AccessSelective Inhibition of β-Catenin/Co-Activator Cyclic AMP Response Element-Binding Protein-Dependent Signaling Prevents the Emergence of Hapten-Induced Atopic Dermatitis-Like Dermatitis
The canonical Wnt/β-catenin signaling pathway is a fundamental regulatory system involved in various biological events. ICG-001 selectively blocks the interaction of β-catenin with its transcriptional co-activator cyclic AMP response element-binding protein (CBP). Recent studies have provided convincing evidence of the inhibitory effects of ICG-001 on Wnt-driven disease models, such as organ fibrosis, cancer, acute lymphoblastic leukemia, and asthma. However, the effects of ICG-001 in atopic dermatitis (AD) have not been investigated. To investigate whether β-catenin/CBP-dependent signaling was contributed in the pathogenesis of AD and ICG-001 could be a therapeutic agent for AD. We examined the effects of ICG-001 in an AD-like murine model generated by repeated topical application of the hapten, oxazolone (Ox). ICG-001 or vehicle alone was injected intraperitoneally every day during the development of AD-like dermatitis arising from once-daily Ox treatment. Ox-induced AD-like dermatitis characterized by increases in transepidermal water loss, epidermal thickness, dermal thickness accompanied by increased myofibroblast and mast cell counts, and serum levels of thymic stromal lymphopoietin and thymus and activation-regulated chemokine, and decreases in stratum corneum hydration, were virtually normalized by the treatment with ICG-001. Elevated serum levels of periostin tended to be downregulated, without statistical significance. These results suggest that β-catenin/CBP-dependent signaling might be involved in the pathogenesis of AD and could be a therapeutic target.